- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02906618
Study of LY3039478 in Healthy Participants
An Absolute Bioavailability Study of LY3039478 in Healthy Subjects Using the Intravenous Tracer Method
The study involves one dose of LY3039478 given by mouth followed by an intravenous infusion (IV) (via a tube linked to a small needle in the vein) of LY3039478. The results of this study will help to answer the following research questions:
- How much LY3039478 gets into the blood stream when given by mouth as a capsule compared to when given by an IV
- How long it takes the body to remove the study drug
- The safety of LY3039478 and any side effects that might be associated with it
Participation in the study is expected to last up to 7 weeks. There will be screening, a single study period, and a follow-up.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Leeds, United Kingdom
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have a body mass index (BMI) of 18.5 to 32.0 kilogram per meter square (kg/m²) inclusive
Exclusion Criteria:
- Have previously completed or withdrawn from this study or any other study investigating LY3039478, and have previously received the investigational product
• Have known allergies to LY3039478, related compounds or any components of the formulation, or history of significant atopy in the opinion of the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LY3039478 - Oral
LY3039478 given once, orally
|
Administered orally
|
Experimental: 13C 15N 2H-LY3039478 - IV
13C 15N 2H-LY3039478 given once, IV
|
Administered IV
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics: Area Under the Concentration versus Time Curve (AUC) from Time Zero to the Last Time Point with a Measurable Concentration (AUC[0 tlast]) of LY3039478 and 3C 15N 2H-LY3039478
Time Frame: Predose through 48 hours after administration of study drug
|
Predose through 48 hours after administration of study drug
|
Pharmacokinetics: AUC from Zero to Infinity (AUC[0 - inf]) of LY3039478 and 3C 15N 2H-LY3039478
Time Frame: Predose through 48 hours after administration of study drug
|
Predose through 48 hours after administration of study drug
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of LY3039478
Time Frame: Predose through 48 hours after administration of study drug
|
Predose through 48 hours after administration of study drug
|
Pharmacokinetics: Time of Cmax (tmax) of LY3039478
Time Frame: Predose through 48 hours after administration of study drug
|
Predose through 48 hours after administration of study drug
|
Pharmacokinetics: Half Life Associated With The Terminal Rate Constant (t1/2) of LY3039478
Time Frame: Predose through 48 hours after administration of study drug
|
Predose through 48 hours after administration of study drug
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 16344
- I6F-MC-JJCG (Other Identifier: Eli Lilly and Company)
- 2016-001073-33 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on LY3039478
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedNeoplasms | Lymphoma | Neoplasm MetastasisUnited States, Spain, Germany, France, United Kingdom, Denmark
-
Eli Lilly and CompanyCompletedT-cell Acute Lymphoblastic Leukemia | T-cell Lymphoblastic LymphomaUnited States, Germany, Israel, France, Italy
-
Eli Lilly and CompanyCompletedSoft Tissue Sarcoma | Breast Cancer | Solid Tumor | Cholangiocarcinoma | Colon CancerUnited States, France, Spain, Denmark
-
Fred Hutchinson Cancer CenterThe Leukemia and Lymphoma Society; Juno Therapeutics, Inc., a Bristol-Myers...TerminatedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
University of AarhusCompleted